

INNOVATORS IN LIVER DISEASE THERAPY

621 Camden Street; Suite 202

San Antonio, TX 78215

Phone: (210) 253-3426

FAX: (210) 477-1808

November 17, 2011

Subject: Brenda M. Alexander

To Whom It May Concern:

Ms Alexander has been undergoing clinical research trials with AMR Group for Hepatitis B and life-threatening related pre-cancerous liver disease for approximately six months. Her treatment consists of daily prescribed medications and multiple mandatory scheduled weekly treatments on an outpatient basis. These treatments are to continue for at least another 24 weeks, and they cannot be missed or skipped if she is to be permitted to remain in this research study. In addition, it should be noted that terminating or interrupting said treatments at any point prior to completion will most likely result in substantial immediate deterioration in Ms. Alexander's health and the likelihood of her eventual recovery.

As a condition of participation in this research study, Ms. Alexander has been required at each treatment event to submit to complete panel of illicit drug, alcohol and tobacco use tests and has consistently passed all such tests. Failure to pass one test will result in Ms. Alexander's immediate expulsion from the treatment regime with severe health consequences to Ms. Alexander.

Likewise, Ms. Alexander has been enrolled as a liver transplant recipient candidate. If a suitable liver should become available, and it is determined that Ms. Alexander's prognosis under the study is not improving, the liver transplant option will be actively pursued. At this time, it is impossible to determine if a liver transplant ultimately will be required, but it is a distinct possibility if a suitable liver should become available.

This letter is provided under Ms. Alexander's request, and hopefully it will prove satisfactory explanation of Ms. Alexander's current status with the AMR Group.

Sincerely

Widi y Kilox

Office Administrator

Precision Cancer Center

126-0331

1010 I'W Loop 410 Suite 100 San Antorio, Texas 78213

O (21.))308,9999

F(21(1)308.6262

To Whom It May Concern:

On December 28, 2011 Ms. Alexander wallevaluated for cervical cancer and precancerous cells and a mass measuring 7m h in her liver. Based on this evaluation, we recommend an emergency hysterector by to address her compromised immune system and continuous haemorrhaging, which are both grave health concerns.

As a result of this condition, she is suffering from severe anemia, cirrhosis of the liver and chronic hepatitis B. Said evaluation presented a white blood cell count of 98, platelet count of 92 and haemoglobin rount of 7.5.

Following her emergency hysterectomy Mil. Alexander will be required to start aggressive radiation and continuing in her interferon treatments. Post surgery, these treatments can be expected to last as long as at least 24 weeks.

Failure to follow the above prescribed treatments, Ms. Alexander's prognosis is poor and most likely will result in her death.

ncologist

Case 3:06-cr-02563-FM Document 79-1 Filed 01/02/12 Page 3 of 3

PRECISION SANCER

Bryan C. Lin, M.D. DEA BL7009500

NAME: Bylinda alexander DATE 12/27/1/
ADDRESS DOB: 8/12/105

Re Patent has an appoint ment
12/28/11 for inetial consult with
12/28/11 for inetial consult with
12/28/11 for inetial consult.